BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

Endometrial cancer clinical trials and catalysts

Active industry-sponsored trials on ClinicalTrials.gov for endometrial cancer: 191 (129 sponsors; 23 newly posted in the last 180 days, 10 stopped in the last 180 days; 13 new-entrant sponsors). Momentum score 10.2, rank 67 of 91 on the disease-area ranking. As of 2026-11-18.

Phase distribution: Early Phase 1 2, Phase 1 66, Phase 2 79, Phase 3 23, Phase 4 2, N/A 19.

Most active sponsors, by phase

SponsorActive trialsBy phaseNew (window)Upcoming readouts
AstraZeneca AZN15P2 6, NA 4, P3 4, P1 101
Merck Sharp & Dohme LLC MRK6P3 4, P2 1, P1 112
GlaxoSmithKline10P2 4, P4 2, P1 1, P3 332
Daiichi Sankyo3P3 1, P2 200
BioNTech SE BNTX2P2 1, P3 100
Evergreen Therapeutics, Inc.2P2 1, P3 101
Genmab GMAB2P2 1, P3 100
Gilead Sciences GILD2P3 1, P2 110
Tesaro, Inc.2P1 1, P3 101
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.1P3 100
Hutchmed HCM1P3 100
Kartos Therapeutics, Inc.1P3 100
Karyopharm Therapeutics Inc KPTIQ1P3 100
Pfizer PFE1P3 100
Shanghai Huaota Biopharmaceutical Co., Ltd. new entrant1P3 110
Eli Lilly and Company LLY8P1 6, P2 211
Radiopharm Theranostics, Ltd RADX3P1 1, EARLY_P1 1, P2 100
Advenchen Pharmaceuticals, LLC. new entrant2P2 220
Convalife (Shanghai) Co., Ltd.2P2 200
Eisai Inc.2P2 201
Elephas2NA 201
Ensem Therapeutics2P2 210
GV20 Therapeutics2P2 201
IDEAYA Biosciences IDYA2P1 200
LigaChem Biosciences, Inc.2P2 1, P1 101

New-entrant sponsors: Shanghai Huaota Biopharmaceutical Co., Ltd., Advenchen Pharmaceuticals, LLC..

Recently stopped trials

Upcoming trial readouts (next 90 days)

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-11-20 est.P3Merck Sharp & Dohme LLC MRKNCT04634877 Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer Endometrial Neoplasmsactive not recruiting990
2026-12 est.P23D Medicines (Sichuan) Co., Ltd.NCT05112991 Study of Envafolimab Alone or With Lenvatinib in Patients With Advanced Endometrial CancerAdvanced Endometrial Cancerrecruiting108
2026-12 est.P2Aadi Bioscience, Inc.NCT05997017 Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial CancerEndometrial Cancer; Endometrioid Tumor; Cancer; Tumor; Recurrent Endometrial Carcinoma; Endometrioidrecruiting29
2026-12 est.P1/P2858 Therapeutics, Inc.NCT06395519 A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid MalignanciesAdvanced or Metastatic Solid Tumors; Breast Cancer; Ovarian Cancer; Prostate Cancer; Epithelial Ovarrecruiting120
2026-12-15 est.P1/P2PMV Pharmaceuticals, Inc PMVPNCT04585750 The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)Advanced Solid Tumor; Advanced Malignant Neoplasm; Metastatic Cancer; Metastatic Solid Tumor; Lung Crecruiting300
2026-12-15 est.P1/P2GV20 TherapeuticsNCT05669430 A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor MalignanciesSolid Tumor, Adult; Refractory Cancer; Endometrial Carcinoma (EC); Squamous Head and Neck Carcinoma;recruiting365
2026-12-31 est.P2Jazz Pharmaceuticals JAZZNCT06695845 A Phase 2 Study of Zanidatamab in Patients With HER2-expressing TumorsBreast Cancer; Gastric Cancer; Esophageal Cancer; Gastroesophageal Cancer; Colorectal Cancer; Endomerecruiting200
2027-01-01 est.P1/P2Second Life TherapeuticsNCT07341737 SL-28 for Advanced Solid TumoursHead & Neck Cancer; Pancreas Carcinoma; Pancreas Cancer, Metastatic; Lung Adenocarcinoma; Lung Cancerecruiting60
2027-02 est.P1/P2Day One Biopharmaceuticals, Inc.NCT05377996 A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid TumorsTriple Negative Breast Cancer; Breast Cancer; Endometrial Cancer; Ovarian Cancer; Fallopian Tube Canrecruiting360

Readouts in the last 180 days

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-08-25P2Hoffmann-La RocheNCT05634499 A Study of Giredestrant in Participants With Grade 1 Endometrial CancerEndometrial Cancercompleted33
2026-06-22 est.P1/P2GlaxoSmithKlineNCT06710847 A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Effectiveness of GSK4418959 Alone or in Combination With Other Anti-cancer Agents in ParticNeoplasms, Colorectal; Solid Tumor; Colon Cancer; Rectal Cancer; Endometrial Canceractive not recruiting14
2026-06-17P1/P2Precision Biologics, Inc DTILNCT03476681 Study of NEO-201 in Solid Tumors Expansion CohortsNon Small Cell Lung Cancer; Head and Neck Squamous Cell Carcinoma; Cervical Cancer; Uterine Canceractive not recruiting121
2026-06-02P1/P2Sensei Biotherapeutics, Inc.NCT05864144 A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid TumorsSolid Tumor, Adult; Advanced Solid Tumor; Head and Neck Cancer; Breast Cancer; Colon Cancer; Pancreacompleted98
2026-05-29P2Incyte Corporation INCYNCT04463771 Safety and Efficacy of Retifanlimab (INCMGA00012) Alone or in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer WhEndometrial Cancercompleted206

Landscape counts: ClinicalTrials.gov, industry lead sponsors, active statuses, via the free hosted BioCatalystFeed MCP tool condition_landscape (query "endometrial cancer"); readouts matched by condition text. Registry counts only; not a forecast.

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.